Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors
- Registration Number
- NCT00225121
- Lead Sponsor
- Pfizer
- Brief Summary
The primary purpose of this study is to study the side effects of PF-00299804 and determine the highest dose that can be safely administered in patients with advanced cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 121
- Malignant solid tumor for which there is no currently approved treatment
- Adequate bone marrow, liver, cardiac, and kidney function
- Cardiac disease
- Anticancer therapy within 4-6 weeks (depending on therapy)
- Pregnant or breast-feeding
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description 1 PF-00299804 open label single arm trial
- Primary Outcome Measures
Name Time Method Safety 6 months
- Secondary Outcome Measures
Name Time Method Pharmacodynamics 6 months Efficacy 6 months Pharmacokinetics 6 months
Trial Locations
- Locations (9)
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Ronald Reagan UCLA Medical Center
🇺🇸Los Angeles, California, United States
UCLA Hematology/Oncology
🇺🇸Los Angeles, California, United States
University of Colorado Hospital
🇺🇸Aurora, Colorado, United States
Vereniging het Nederlandse Kanker Instituut
🇳🇱Amsterdam, Netherlands
UCLA Oncology Center
🇺🇸Los Angeles, California, United States
UCLA Santa Monica Hematology/Oncology
🇺🇸Santa Monica, California, United States
UCLA Hematology Oncology - Santa Monica
🇺🇸Santa Monica, California, United States